Questcor Pharmaceuticals

Citadel Securities has published a report on Questcor (NASDAQ: QCOR) raising the price target significantly and upgrading the company's stock from Neutral to Edge Positive. In the report, Citadel Securities wrote, "We anticipate a robust ramp in Acthar revenues from Nephrotic Syndrome based on a...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Oppenheimer has raised the price target on Questcor Pharmaceuticals (NASDAQ: QCOR) from $19 to $23 and maintains its Outperform rating.

Oppenheimer has raised the price target on Questcor Pharmaceuticals (NASDAQ: QCOR) from $14 to $19.

On 10/27, Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) reported 3Q EPS of $0.18, “above our estimate of $0.15 and consensus of $0.15,” Oppenheimer reports. “Importantly, we note that Acthar revenues were $31.3M, above our $30.7M estimate, driven largely by strong MS sales growth,” Oppenheimer...